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Abstract Type V adenylyl cyclase (AC) was stably over- 
expressed in HEK293 cells (293AC-V). Forskolin-stimulated 
cAMP accumulation in 293AC-V was 5 times as great as that in 
control cells. PMA, a protein kinase C (PKC) activator, 
enhanced cAMP accumulation in 293AC-V cells dose-and 
time-dependently and this enhancement was abolished by 
staurosporine. Insulin also enhanced cAMP accumulation in 
293AC-V cells. Co-transfection of PKC-~, but not PKC-~ 
potentiated the effects of insulin. These data suggest hat type V 
AC activity is regulated in cells by PKC isoenzymes through 
different extracellular stimuli. 
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I. Introduction 
Regulators of adenylyl cyclase (AC) activity are not re- 
stricted to Gs and Gi proteins; protein kinase C (PKC), a 
major mediator in the phosphatidylinositol signal, is another 
key regulator. Over years, numerous investigators have de- 
monstrated that activation of PKC by phorbol esters alters 
the intracellular cAMP levels in various tissues and cultured 
cells. However, the direction and degree of this alteration have 
been variable among studies [1]. Investigators have tried to 
explain this variability by the different sites of interaction; 
PKC may phosphorylate multiple components within the 
cAMP signaling system, such as receptors, G proteins and 
AC [2-5]. 
Although phorbol ester has been used as a classic PKC 
activator, recent cloning studies have elucidated the presence 
of a group of PKC isoenzymes, i.e. atypical PKC isoenzymes, 
that are insensitive to diacylglycerol, and thus to phorbol ester 
[6]. These isoenzymes are difficult to study because of the lack 
of specific activators and inhibitors [7,8]. More recent studies 
have suggested that atypical isoenzymes are activated by ex- 
tracellular stimuli such as insulin and other growth factors [9- 
11]. 
In our previous report using purified enzymes, we have 
shown that PKC directly phosphorylates and activates type 
v AC in a PKC isoenzyme-dependent manner [5]. In particu- 
lar, we have demonstrated that PKC-~, an atypical isoenzyme, 
activates type V AC in vitro. In this study, we have investi- 
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gated (1) whether the phorbol ester treatment of intact cells 
recapitulates the activation of type V AC by PKC observed in 
vitro and (2) whether an extracellular stimulus that potentially 
activates PKC-~ also activates type V AC in intact cells. 
2. Materials and methods 
2.1. Stable transfection of human embryonic kidney (HEK) cell 
HEK 293 cells were grown at 37°C in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal bovine serum in a humidified 
95% air/5% CO2 incubator. Cells were transfected with either the type 
V AC cDNA in pcDNAneo (AC-V) or pcDNAneo alone (control) 
using the calcium phosphate method. Neomycin-resistant cells were 
selected in culture medium containing G418 (500 gg/ml). 
2.2. Transient ransfection of HEK 293 cell 
Entire PKC-a or PKC-~ coding cDNA were constructed in the 
SRD expression vector [12]. These expression vectors were transfected 
into 293AC-V cells using the double transfection method as described 
previously [13]. 1 day after transfection, the ceils were subdivided into 
12-well plates and incubated for an additional 2 days prior to 
[3 H]adenine labeling. 
2.3. [all]Adenine labeling and cAMP accumulation assay 
Cyclic AMP accumulation in intact cells was measured according to 
the method of Wong et al. [14]. The cells were placed in a serum-free 
culture medium containing 0.1% bovine serum albumin and 
[all]adenine (0.5 gCi/well) for 18 h. The cells were then washed 
once with a HEPES balanced salt solution (HBSS) (137 mM NaC1, 
5 mM KC1, 1.2 mM CaC12, 1 mM MgC12, 20 mM HEPES (pH 7.5), 
10 mM D-glucose and 0.2% phenol red) and pretreated with HBSS 
containing 0.5 mM 1-methyl-3-isobutylxanthine (IBMX) and various 
reagents for 10 min. Reactions were started by adding 10 gM forsko- 
lin and other reagents, and terminated by addition of 12% (w/v) tri- 
chloroacetic acid, 0.25 mM ATP and 0.25 mM cAMP after the in- 
dicated times. [3H]ATP and [3H]cAMP were separated according to 
the method of Salomon et al. [15]. cAMP production is expressed as 
[3H]cAMP/([aH]cAMP + [aH]ATP)× 103. All assays were performed 
in duplicate or triplicate, and the values are shown as means + S.E.M. 
Student's t-test was used for comparisons of groups. 
3. Results and discussion 
3.1. Effects of  PMA on cAMP accumulation in 293 cells 
In cells stably transfected with type V AC (293AC-V), for- 
skolin-stimulated cAMP accumulation was 5 times as great as 
that in control cells. Treatment of 293AC-V cells with PMA 
(100 gM), PKC-activating phorbol ester, significantly en- 
hanced forskolin-stimulated cAMP accumulation (Fig. 1). 
Unstimulated cAMP accumulation i 293AC-V cells, as well 
as cAMP accumulation i control cells (Fig. 1), was enhanced 
slightly by the same treatment (data not shown). 
3.2. Time course of  cAMP accumulation 
Forskolin increased cAMP accumulation i 293AC-V cells 
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in a time-dependent manner. The accumulation reached a 
plateau at 20 min after initiating incubation. The time course 
of cAMP accumulation was similar regardless of the treat- 
ment with PMA (Fig. 2). 
3.3. PMA dose response of cAMP accumulation 
PMA treatment of 293AC-V cells enhanced cAMP accumu- 
lation in a dose-dependent manner with an ECs0 value of 
2 X 10 -z M (Fig. 3). ctPDD, an inactive phorbol ester analog, 
had no effects on cAMP accumulation. Maximal cAMP accu- 
mulation was achieved with 100 ~tM PMA. At this concentra- 
tion, the cAMP levels were increased by 50-100%. 
3.4. Effects of staurosporine on PMA-induced cAMP 
accumulation 
Staurosporine, a potent and specific PKC inhibitor, abol- 
ished the PMA-induced enhancement of cAMP accumulation 
in 293AC-V cells (Fig. 4). 
The above data indicate that PMA enhanced cAMP accu- 
mulation in 293AC-V cells through activation of endogenous, 
PMA-sensitive PKC. Since type V AC is responsible for most 
of the catalytic activity in 293AC-V cells (,-~ 80%), we con- 
clude that type V AC is stimulated by phorbol ester in intact 
cells. It was previously shown that phorbol esters stimulate 
both Ca/calmodulin-sensitive (type I and III) and Ca/calmo- 
dulin-insensitive (type II) isoforms [16-18]. Thus, stimulation 
of AC by phorbol ester may be a more general phenomenon 
among AC isoforms although the exact mechanisms and de- 
gree of this stimulation may vary among them. 
We also examined the effects of purified PKC-ct on type V 
AC in membranes prepared from mammalian cells (CMT 
300 
$ 
==o ~O 
OO 
<I: 100 
O 
Me=SO 
Insulin 
¢/} / /  
f / / J . /  
/ / ' / / /  
/ / / / /  
/ f / / /  
/ - / - / / -  / 
/ / ' / / /  
/ / / / /  
/ / / / /  
/ / / ' J /  
/ / / / /  
/ / / / ' /  
/ / / / /  
/ / J / /  
f / / / J  
/ i / / i  
/ / J / J  
/ / / / /  
293 Ct 293 AC-V 
Fig. 1. Effects of phorbol ester on 293AC-V and control cells. 
293AC-V (293 AC-V) and control (293 Ct) ceils were treated with 
Me2SO (vehicle) (open bars), 100 nM PMA (shaded bars), or 100 
nM insulin (closed bars) for 10 min, followed by stimulation with 
10 IxM forskolin for 30 min. Cyclic AMP accumulation was deter- 
mined as described in section 2. *P < 0.05; **P < 0.0! vs. Me2SO 
(n = 7-12). 
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Fig. 2. Time course of cAMP accumulation i  293AC-V cells stimu- 
lated by PMA. 293AC-V cells were pre-treated with 100 nM PMA 
(closed circles) or Me2SO (open circles) for 10 re_in, followed by in- 
cubation in the presence of 10 ~tM forskolin for the indicated time. 
Cyclic AMP accumulation was determined asdescribed in section 2. 
cells) or insect cells (High Five cells). However, the maximal 
stimulation of type V AC in such membrane preparations was 
weaker (10-20%) than that obtained in intact cells (,~ 100%, 
see Fig. 1) (data not shown). We do not know, however, why 
PKC could achieve higher stimulation of type V AC in intact 
cells than in membrane preparations. Another PMA-sensitive 
PKC isoenzyme, which stimulates type V AC more potently 
than PKC-~, may exist in intact cells. Alternatively, proteins 
that facilitate the transportation f PKC to type V AC in the 
membrane may be involved in intact cells. It has been shown 
that PKC translocates to the membrane upon stimulation [6]. 
The presence of proteins has been demonstrated, such as 
RACK (receptors for activated C-kinase), that recognize an 
active form of PKC and specify the localization of PKC iso- 
enzymes within the cell [19,20]. These cellular trafficking 
mechanisms may facilitate the encountering of PKC with 
type V AC in intact cells, achieving the optimal stoichiometry 
for the stimulation of type V AC in the membrane. Indeed, 
when both enzymes, PKC and type V AC, were purified and 
incubated together, the maximal stimulation of type V AC by 
PKC increased significantly as shown by us previously [5]. 
3.5. Effects of insulin on cAMP accumulation in 293 cells 
We also examined the effects of insulin on cAMP accumu- 
lation in 293AC-V cells (Fig. 1). Insulin enhanced forskolin- 
stimulated cAMP accumulation although the degree of en- 
hancement was lower (,~20%) than that by PMA (50-100%). 
3.6. Effects of coexpression of PKC on PMA, 
insulin-stimulated cAMP accumulation 
In order to examine the contribution of specific PKC iso- 
enzymes to the enhancement of cAMP accumulation in 
293AC-V cells, we transiently overexpressed PKC-ct, a con- 
ventional isoenzyme, and PKC-~, an atypical isoenzyme [6]. 
We have chosen a transient PKC expression system since 
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Fig. 3. Dose-dependent stimulation of type V AC by phorbol esters. 
293AC-V cells were treated with either aPDD, an inactive phorbol 
ester (squares), or PMA (circles) for 10 min, followed by incubation 
in the presence of 10 I.tM forskolin for 30 min. Cyclic AMP accu- 
mulation was determined as described in section 2. 
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Fig. 4. Effects of staurosporine on the PMA-mediated enhancement 
of cAMP accumulation. 293AC-V cells were pre-incubated with 100 
nM staurosporine (+) or its vehicle, Me2SO (--) for 30 min, fol- 
lowed by treatment with 100 nM PMA or Me2SO for 10 min. The 
ceils were then incubated in the presence of 10 gM forskolin. Cyclic 
AMP accumulation was determined as described in section 2. 
**P < 0.01 vs. Me2SO (n = 4). 
stable co-expression of PKC may modify the expression of 
AC in the cell. 
Overexpression of these PKC isoenzymes by itself did not 
alter cAMP accumulation in 293AC-V cells (control cells, 
152.5 + 10.0; cells overexpressing PKC-~, 162.0 + 15.5; PKC- 
4, 164.1 + 10.1, n = 6-13, P = N.S.). PMA treatment of these 
cells enhanced cAMP accumulation by 60-80% (Fig. 5). How- 
ever, the degree of enhancement did not differ among these 
cells, including those overexpressing PKC-a,  a PMA-sensitive 
isoenzyme. The amount of endogenous PMA-sensitive PKC 
isoenzymes in 293 cells may already be functionally saturated 
to stimulate type V AC activity. Alternatively, PKC-~ may 
not be involved in cross-talk between the cAMP signal and 
the diacylglycerol signal in 293 cells. 
Insulin enhanced cAMP accumulation in 293AC-V by 
,~ 15% (Fig. 1). In clear contrast to the above results, when 
the cells were transfected with PKC-~, the insulin-mediated 
enhancement of cAMP accumulation was further potentiated 
(~ 30%) (Fig. 5). Cells overexpressing PKCqx did not show 
any further enhancement, indicating that the effect of in- 
sulin on cAMP accumulation was unique to the expression of 
PKC@ 
In contrast to the conventional PKC isoenzymes that are 
activated by Ca and diacylglycerol, PKC-~ is activated by 
arachidonic acid and phosphatidylinositol 3,4,5-triphosphate 
(PIP3) [9,10], which are products of insulin or other growth 
factor receptor stimulation [21,22]. Indeed, a recent study has 
shown that PKC-~ is involved in the physiological functions 
of insulin in vivo [11]. Stimulation of these receptors initiates 
a cascade of phosphorylation reaction within the cell, promot- 
ing cellular growth and differentiation [23]. It is interesting to 
note that investigators have demonstrated that insulin also 
modulates the cAMP signal [24,25]. Our study suggests that 
insulin regulates the cAMP signal at the level of AC through 
activating PKC-~. A more recent study has demonstrated that 
epidermal growth factor enhances cAMP production [26] and 
that this enhancement is unique to the type V isoform [27]. 
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Fig. 5. Transient expression of PKC isoenzymes and its effect on 
293AC-V cells. 293AC-V cells were transiently transfected with con- 
trol plasmid (open bars), PKC-o~ (shaded bars), and PKC-~ (closed 
bars). These cells were pre-incubated with 100 nM PMA (PMA) or 
100 nM insulin (Insulin) for 10 min, followed by incubation in the 
presence of 10 gM forskolin. Cyclic AMP accumulation was deter- 
mined as described in section 2. The data are shown as % increases 
from the cAMP accumulation in non-treated cells. *P < 0.05 
(n = 6-12). 
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We have previously shown that PKC-~ stimulates type V AC 
more potently than PKC-~ [5]. We do not know, however, 
whether the stimulation of AC by insulin is unique to the type 
V isoform. 
In summary, the catalytic activity of type V AC increased in 
response to PMA and insulin stimulation. In particular, the 
effect of insulin was augmented by transfecting PKC-~. These 
data suggest hat type V AC is regulated by both PMA-sensi- 
tive and-insensitive PKC isoenzymes in intact cells, coordinat- 
ing the activities of these two signal transduction pathways at 
the level of this enzyme. 
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